(Q54313994)

27 May 2018

title

Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas. (English)

1 reference

27 May 2018

main subject

phase II clinical trial

0 references

nintedanib

1 reference

ChEBI release 2020-05-28

20

David A Reardon

1 reference

27 May 2018

21

Patrick Y Wen

1 reference

27 May 2018

Eudocia Q Lee

6

Eudocia Q Lee

1 reference

27 May 2018

Alona Muzikansky

8

Alona Muzikansky

1 reference

27 May 2018

Keith L Ligon

19

Keith L Ligon

1 reference

27 May 2018

Lakshmi Nayak

5

Lakshmi Nayak

1 reference

27 May 2018

Mikael Rinne

7

Mikael L Rinne

1 reference

27 May 2018

Andrew D Norden

1

Andrew D Norden

1 reference

27 May 2018

Sandra F Ruland

15

Sandra F Ruland

1 reference

27 May 2018

Debra C LaFrankie

12

Debra C LaFrankie

1 reference

27 May 2018

Sarah C Gaffey

17

Sarah C Gaffey

1 reference

27 May 2018

Manmeet S Ahluwalia

3

Manmeet S Ahluwalia

1 reference

27 May 2018

Benjamin Purow

10

Benjamin Purow

1 reference

27 May 2018

Christine McCluskey

18

Christine McCluskey

1 reference

27 May 2018

Katrina Smith Korfmacher

16

Katrina H Smith

1 reference

27 May 2018

Glenn J Lesser

4

Glenn J Lesser

1 reference

27 May 2018

Jennifer A Rifenburg

14

Jennifer A Rifenburg

1 reference

27 May 2018

Julee R Pulverenti

13

Julee R Pulverenti

1 reference

27 May 2018

author name string

David Schiff

2

1 reference

27 May 2018

Jorg Dietrich

9

1 reference

27 May 2018

Lisa M Doherty

11

1 reference

27 May 2018

publication date

22 October 2014

1 reference

27 May 2018

Journal of Neuro-Oncology

published in

1 reference

27 May 2018

volume

121

1 reference

27 May 2018

issue

2

1 reference

27 May 2018

page(s)

297-302

1 reference

27 May 2018

https://scigraph.springernature.com/pub.10.1007/s11060-014-1631-y

exact match

0 references

cites work

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1631-Y

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1631-Y

Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1631-Y

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1631-Y

Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1631-Y

BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1631-Y

Phase II open-label study of nintedanib in patients with recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1631-Y

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1631-Y

Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1631-Y

A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1631-Y

Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1631-Y

Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1631-Y

Phase I Safety, Pharmacokinetic, and Biomarker Study of BIBF 1120, an Oral Triple Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1631-Y

Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1631-Y

Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1631-Y

Monoclonal antibodies in neuro-oncology: Getting past the blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1631-Y

Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1631-Y

In vitro drug response and efflux transporters associated with drug resistance in pediatric high grade glioma and diffuse intrinsic pontine glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1631-Y

Thromboembolic disease in patients with high-grade glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1631-Y

Colon perforation during antiangiogenic therapy for malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1631-Y

Medical management of brain tumor patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1631-Y

How large should a phase II trial of a new drug be?

21 January 2018

1 reference

12 December 2020

Inhibition of fibroblast growth factor/fibroblast growth factor receptor activity in glioma cells impedes tumor growth by both angiogenesis-dependent and -independent mechanisms

1 reference

12 December 2020

Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy

1 reference

12 December 2020

Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms

1 reference

12 December 2020

10.1007/S11060-014-1631-Y

Identifiers

DOI

1 reference

27 May 2018

1 reference

27 May 2018